Berkshire Sterile Manufacturing to Host Webinar on Formulation Development for First-in-Human Studies Lee, MA, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM) is pleased to announce their ninth webinar in their webinar series, Sterile Filling 101, which will be held on...

Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma. Hunt Valley, MD, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pharmaceutics International, Inc. (Pii), a contract development and manufacturing organization (CDMO), proudly celebrates a first-in-human Phase I...

PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update Conference call to be held on May 21, 2019 at 4:30 p.m. Eastern time NEW YORK, May 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...

PAVmed Announces First Human CarpX™ Procedures First nine patients undergo successful CarpX procedures as part of FIH clinical safety study NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...

Rhizen Pharmaceuticals S.A. announces initiation of a "First in Human" Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies La Chaux-de-Fonds, Switzerland, Dec. 6, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced the initiation of a "first in human" Phase-1 study of RP6530, a...